Transscleral diode laser cyclophotocoagulation after baerveldt glaucoma implant surgery

Research output: Contribution to journalArticlepeer-review

7 Scopus citations


PURPOSE: To evaluate the safety and efficacy of transscleral cyclophotocoagulation (TSCPC) in patients requiring intraocular pressure (IOP) reduction despite prior Baerveldt glaucoma implant (BGI) surgery. PARTICIPANTS AND METHODS: Twenty eyes of 20 patients who had previously undergone BGI placement and subsequently underwent TSCPC with the red (810 nm) diode laser between April 2005 and January 2010 were retrospectively reviewed. RESULTS: All patients underwent BGI placement an average of 34.7±24.2 months before TSCPC. The mean follow-up period after TSCPC was 25.6±17.4 months (range, 2.3 to 56.5 mo). IOPs were reduced from a mean of 21.8±4.6 to 10.8±3.2 mm Hg at the most recent follow-up, which represents a 50.2% reduction in mean IOP. Successful postoperative IOP control was achieved in 16 (80%) of 20 patients. The number of glaucoma medications decreased from 4.2±0.6 to 2.2±1.2. The life-table success rate was 78.6% at 12, 24, and 36 months. Postoperative complications included persistent corneal edema in 1 patient and both persistent corneal edema and cystoid macular edema in another patient. Both patients sustained a >2 line reduction in Snellen visual acuity. CONCLUSIONS: TSCPC is safe and effective in the management of patients requiring IOP reduction after BGI surgery. Although our sample size was limited, the safety profile of TSCPC after BGI seems promising.

Original languageEnglish
Pages (from-to)405-409
Number of pages5
JournalJournal of Glaucoma
Issue number6
StatePublished - Aug 2014
Externally publishedYes


  • Baerveldt glaucoma implant
  • complications
  • outcomes
  • refractory glaucoma
  • transscleral diode laser cyclophotocoagulation


Dive into the research topics of 'Transscleral diode laser cyclophotocoagulation after baerveldt glaucoma implant surgery'. Together they form a unique fingerprint.

Cite this